172 related articles for article (PubMed ID: 38627450)
21. Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy.
Song Z; Tu D; Tang G; Liu N; Tai Z; Yang J; Wang Y
Haematologica; 2023 Aug; 108(8):2067-2079. PubMed ID: 36794498
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies.
Saiz LC; Leache L; Gutiérrez-Valencia M; Erviti J; Rojas Reyes MX
Ther Adv Hematol; 2023; 14():20406207231168211. PubMed ID: 37138698
[TBL] [Abstract][Full Text] [Related]
23. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I; Chabannon C; Bader P; Basak GW; Bonig H; Ciceri F; Corbacioglu S; Duarte RF; Einsele H; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Robinson S; Saccardi R; Sanchez-Guijo F; Snowden JA; Srour M; Styczynski J; Urbano-Ispizua A; Hayden PJ; Kröger N
Haematologica; 2020; 105(2):297-316. PubMed ID: 31753925
[TBL] [Abstract][Full Text] [Related]
24. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Pennisi M; Jain T; Santomasso BD; Mead E; Wudhikarn K; Silverberg ML; Batlevi Y; Shouval R; Devlin SM; Batlevi C; Brentjens RJ; Dahi PB; Diamonte C; Giralt S; Halton EF; Maloy M; Palomba ML; Sanchez-Escamilla M; Sauter CS; Scordo M; Shah G; Park JH; Perales MA
Blood Adv; 2020 Feb; 4(4):676-686. PubMed ID: 32084260
[TBL] [Abstract][Full Text] [Related]
25. Current understanding and management of CAR T cell-associated toxicities.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2024 May; ():. PubMed ID: 38769449
[TBL] [Abstract][Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
27. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
Ragoonanan D; Khazal SJ; Abdel-Azim H; McCall D; Cuglievan B; Tambaro FP; Ahmad AH; Rowan CM; Gutierrez C; Schadler K; Li S; Di Nardo M; Chi L; Gulbis AM; Shoberu B; Mireles ME; McArthur J; Kapoor N; Miller J; Fitzgerald JC; Tewari P; Petropoulos D; Gill JB; Duncan CN; Lehmann LE; Hingorani S; Angelo JR; Swinford RD; Steiner ME; Hernandez Tejada FN; Martin PL; Auletta J; Choi SW; Bajwa R; Dailey Garnes N; Kebriaei P; Rezvani K; Wierda WG; Neelapu SS; Shpall EJ; Corbacioglu S; Mahadeo KM
Nat Rev Clin Oncol; 2021 Jul; 18(7):435-453. PubMed ID: 33608690
[TBL] [Abstract][Full Text] [Related]
29. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT).
Sanchez-Guijo F; Vives J; Ruggeri A; Chabannon C; Corbacioglu S; Dolstra H; Farge D; Gagelmann N; Horgan C; Kuball J; Neven B; Rintala T; Rocha V; Sanchez-Ortega I; Snowden JA; Zwaginga JJ; Gnecchi M; Sureda A
Cytotherapy; 2024 Feb; ():. PubMed ID: 38416085
[TBL] [Abstract][Full Text] [Related]
30. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
31. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
Nagle SJ; Murphree C; Raess PW; Schachter L; Chen A; Hayes-Lattin B; Nemecek E; Maziarz RT
Am J Hematol; 2021 Apr; 96(4):455-461. PubMed ID: 33529419
[TBL] [Abstract][Full Text] [Related]
32. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
33. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
34. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
Mucha SR; Rajendram P
Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
[TBL] [Abstract][Full Text] [Related]
35. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
36. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
37. Current status of CAR-T cell therapy for pediatric hematologic malignancies.
Hiramatsu H
Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980
[TBL] [Abstract][Full Text] [Related]
38. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
[TBL] [Abstract][Full Text] [Related]
39. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group.
Spanjaart AM; Ljungman P; de La Camara R; Tridello G; Ortiz-Maldonado V; Urbano-Ispizua A; Barba P; Kwon M; Caballero D; Sesques P; Bachy E; Di Blasi R; Thieblemont C; Calkoen F; Mutsaers P; Maertens J; Giannoni L; Nicholson E; Collin M; Vaz CP; Metafuni E; Martinez-Lopez J; Dignan FL; Ribera JM; Nagler A; Folber F; Sanderson R; Bloor A; Ciceri F; Knelange N; Ayuk F; Kroger N; Kersten MJ; Mielke S
Leukemia; 2021 Dec; 35(12):3585-3588. PubMed ID: 34750508
[No Abstract] [Full Text] [Related]
40. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
